PROCEPT BioRobotics Sees Strong Revenue Growth in Q1 2025

Procept Biorobotics Corp. ( (PRCT) ) has released its Q1 earnings. Here is a breakdown of the information Procept Biorobotics Corp. presented to its investors.

PROCEPT BioRobotics Corporation, a surgical robotics company specializing in transformative urology solutions, has reported significant financial growth in its first quarter of 2025. The company, known for its innovative robotic systems like the AQUABEAM and HYDROS, has seen a 55% increase in total revenue compared to the same period last year, reaching $69.2 million. This growth is attributed to strong sales of robotic systems and consumables in the U.S. and a remarkable 104% increase in international revenue.

Key financial metrics reveal a robust performance with U.S. handpiece and consumables revenue increasing by 61% and U.S. system and rental revenue growing by 31%. The company sold 43 new robotic systems in the U.S., contributing to a total U.S. revenue of $60.3 million. Gross margins improved to 64% due to operational efficiencies and higher selling prices, despite a net loss of $24.7 million, which is a slight improvement from the previous year’s loss.

The company has raised its revenue guidance for the full year 2025 to $323 million, reflecting a 44% growth over the previous year. PROCEPT BioRobotics anticipates maintaining a gross margin of approximately 64.5%, although potential global tariff impacts could slightly affect this figure. Operating expenses are projected to remain consistent with previous guidance, and the company expects an adjusted EBITDA loss of $35 million for the year.

Looking ahead, PROCEPT BioRobotics remains optimistic about its growth trajectory, driven by the continued adoption of its Hydros system and Aquablation therapy. The company is confident in its strategic position and aims to further solidify its presence in the urology sector, leveraging its innovative solutions to enhance patient care and expand its market reach.